Filing Details

Accession Number:
0001209191-24-001280
Form Type:
4
Zero Holdings:
No
Publication Time:
2024-01-09 19:08:05
Reporting Period:
2024-01-06
Accepted Time:
2024-01-09 19:08:05
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1370053 Anaptysbio Inc ANAB Pharmaceutical Preparations (2834) 203828755
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1711462 F. Paul Lizzul C/O Anaptysbio, Inc.
10770 Wateridge Circle, Suite 210
San Diego CA 92121
Chief Medical Officer No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2024-01-06 6,145 $0.00 12,672 No 4 M Direct
Common Stock Disposition 2024-01-08 2,554 $21.81 10,118 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Restricted Stock Unit Disposition 2024-01-06 6,145 $0.00 6,145 $0.00
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
18,435 No 4 M Direct
Footnotes
  1. Each restricted stock award ("RSU") represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement for no consideration.
  2. The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of RSUs. The sale was to satisfy tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person.
  3. The RSUs vests as to 25% of the total RSUs annually commencing on January 6, 2024 until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date.